AllSci News
Daiichi Sankyo Q1 FY2026: Datroway delay, R-DXd uncertainty and CD25 ADC debut
Daiichi Sankyo's Q1 FY2027 earnings call, held on July 31, 2026, surfaced three material pipeline developments: a delayed data readout for Datroway in...
Leads Biolabs' NewCo Oblenio advances CD19×BCMA×CD3 trispecific into clinic
Oblenio Bio has dosed the first patients in a Phase Ia first-in-human trial of LBL-051, a CD19×BCMA×CD3 tri-specific T-cell engager being evaluated in...
Cirrus adds SERI, Duke-NUS collaboration and extends seed financing
Cambridge, Massachusetts-based Cirrus Therapeutics, Inc., an ocular immunology biotech focused on chronic blinding diseases, has announced an expanded...
Researchers harness pre-existing COVID-19 immunity to boost experimental cancer vaccine
Researchers at Case Western Reserve University and Cleveland-based Celloram Inc. have demonstrated that a dendritic cell cancer vaccine designed to co-opt...
Tumor-distal lymph nodes may preserve immune reservoir supporting checkpoint therapy in NSCLC
Researchers at China-based Tianjin Medical University have identified that mediastinal lymph nodes anatomically distant from the primary tumor — previously...
Photocure and Asieris clash over USD 11m China milestone for Cevira approval
Norway-based Photocure ASA (OSE: PHO) faces a widened legal dispute with China-based Asieris Pharmaceuticals (SSE: 688176) over a USD 11 million milestone...
XellSmart's off-the-shelf Parkinson's cell therapy gets FDA fast-track treatment
China-based XellSmart Biopharmaceutical Co., Ltd. announced on July 28, 2026 that the US FDA has granted Fast Track Designation (FTD) to XS411, an...
Pathos AI commits to USD 2.2b deal for first-in-class TROP2/HER3 bispecific ADC from Alphamab
Pathos AI has licensed exclusive ex-Greater China rights to JSKN016, a bispecific antibody-drug conjugate (ADC) simultaneously targeting TROP2 and HER3,...
FDA approves Pluvicto in earlier-stage prostate cancer, expanding Novartis's radioligand franchise
The US FDA has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for patients with...
Zai Lab's zoci takes FDA orphan drug designation for neuroendocrine carcinomas
Zai Lab (Nasdaq: ZLAB) announced receipt of US FDA orphan drug designation for zocilurtatug pelitecan (zoci, formerly ZL-1310), its delta-like ligand 3...
BlossomHill unveils USD 125m IPO terms as lead EGFR program advances
San Diego-based BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage oncology company whose lead program targets a form of EGFR-mutant lung...
AstraZeneca licenses preclinical ERα PROTAC AZD4241 to Pathos AI
Pathos AI, a privately held AI-native oncology company, has entered a collaboration and co-exclusive licensing agreement with AstraZeneca (LSE/Nasdaq: AZN)...
Otsuka's sibeprenlimab stabilizes kidney function decline to near-baseline rate in IgAN Phase III
Otsuka reported two-year kidney function data from the Phase III VISIONARY trial of sibeprenlimab (Voyxact) in IgA nephropathy (IgAN) that complete the...
China grants breakthrough status for InnoCare's orelabrutinib-mesutoclax combo in MZL
China-based InnoCare Pharma (HKEX: 09969; SSE: 688428) announced that the orelabrutinib mesutoclax combination has been granted Breakthrough Therapy...
Roche partners with Evexta Bio to test dual-node inhibitor against resistant breast cancer
France-based Evexta Bio S.A. and Roche announced a clinical trial collaboration and supply agreement to evaluate rupitasertib in combination with...
The AllSci Brief
Free, systematic R&D and deal news. Daily.